{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T11:40:44Z","timestamp":1792237244877,"version":"4.4.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T00:00:00Z","timestamp":1740355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Res"],"DOI":"10.1186\/s13550-025-01207-9","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T17:43:21Z","timestamp":1740419001000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Measurement of specific and nonspecific tissue uptake of antibodies in tumor by SPECT imaging and nonlinear compartmental modeling"],"prefix":"10.1186","volume":"15","author":[{"given":"Nicholas","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffrey Del","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Fan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory Z.","family":"Ferl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Andrew","family":"Boswell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,24]]},"reference":[{"key":"1207_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/clpt.2008.170","volume":"84","author":"W Wang","year":"2008","unstructured":"Wang W, Wang E, Balthasar J. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 2008;84:548\u201358.","journal-title":"Clin Pharmacol Ther"},{"key":"1207_CR2","first-page":"576","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT: Pharmacomet Syst Pharmacol. 2017;6:576\u201388.","journal-title":"CPT: Pharmacomet Syst Pharmacol"},{"key":"1207_CR3","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1080\/19420862.2017.1337619","volume":"9","author":"MJ Eigenmann","year":"2017","unstructured":"Eigenmann MJ, Fronton L, Grimm HP, Otteneder MB, Krippendorff B-F. Quantification of IgG monoclonal antibody clearance in tissues. mAbs. 2017;9:1007\u201315.","journal-title":"mAbs"},{"key":"1207_CR4","doi-asserted-by":"publisher","first-page":"689","DOI":"10.4161\/mabs.28254","volume":"6","author":"V Yip","year":"2014","unstructured":"Yip V, Palma E, Tesar DB, Mundo EE, Bumbaca D, Torres EK, et al. Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor. mAbs. 2014;6:689\u201396.","journal-title":"mAbs"},{"key":"1207_CR5","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1208\/s12248-012-9374-1","volume":"14","author":"CA Boswell","year":"2012","unstructured":"Boswell CA, Bumbaca D, Fielder PJ, Khawli LA. Compartmental tissue distribution of antibody therapeutics: experimental approaches and interpretations. AAPS J. 2012;14:612\u20138.","journal-title":"AAPS J"},{"key":"1207_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.2967\/jnumed.120.253146","volume":"62","author":"HK Gan","year":"2021","unstructured":"Gan HK, Burge M, Solomon B, Lee ST, Holen KD, Zhang Y, et al. A phase 1 and biodistribution study of ABT-806i, an 111 In-Radiolabeled conjugate of the Tumor-Specific Anti-EGFR antibody ABT-806. J Nucl Med. 2021;62:787\u201394.","journal-title":"J Nucl Med"},{"key":"1207_CR7","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1007\/s11307-015-0912-y","volume":"18","author":"AC Lockhart","year":"2016","unstructured":"Lockhart AC, Liu Y, Dehdashti F, Laforest R, Picus J, Frye J, et al. Phase 1 evaluation of [64Cu]DOTA-Patritumab to assess dosimetry, apparent receptor occupancy, and safety in subjects with advanced solid tumors. Mol Imaging Biol. 2016;18:446\u201353.","journal-title":"Mol Imaging Biol"},{"key":"1207_CR8","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1007\/s00259-023-06109-3","volume":"50","author":"N Stergiou","year":"2023","unstructured":"Stergiou N, Wuensche TE, Schreurs M, Mes I, Verlaan M, Kooijman EJM, et al. Application of 89Zr-DFO*-immuno-PET to assess improved target engagement of a bispecific anti-amyloid-\u00df monoclonal antibody. Eur J Nucl Med Mol Imaging. 2023;50:1306\u201317.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1207_CR9","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.2967\/jnumed.118.220095","volume":"60","author":"SV Hartimath","year":"2019","unstructured":"Hartimath SV, Alizadeh E, Solomon VR, Chekol R, Bernhard W, Hill W, et al. Preclinical evaluation of 111In-Labeled pegylated Maytansine nimotuzumab drug conjugates in EGFR-Positive Cancer models. J Nucl Med. 2019;60:1103\u201310.","journal-title":"J Nucl Med"},{"key":"1207_CR10","doi-asserted-by":"publisher","first-page":"25103","DOI":"10.18632\/oncotarget.8390","volume":"7","author":"S-P Williams","year":"2016","unstructured":"Williams S-P, Ogasawara A, Tinianow JN, Flores JE, Kan D, Lau J, et al. ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1. Oncotarget. 2016;7:25103\u201312.","journal-title":"Oncotarget"},{"key":"1207_CR11","doi-asserted-by":"publisher","first-page":"3354","DOI":"10.3390\/molecules27103354","volume":"27","author":"CS Kramer","year":"2022","unstructured":"Kramer CS, Dimitrakopoulou-Strauss A. Immuno-Imaging (PET\/SPECT)\u2013Quo vadis?? Molecules. 2022;27:3354.","journal-title":"Molecules"},{"key":"1207_CR12","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41568-023-00576-4","volume":"23","author":"J Schwenck","year":"2023","unstructured":"Schwenck J, Sonanini D, Cotton JM, Rammensee H-G, la Foug\u00e8re C, Zender L, et al. Advances in PET imaging of cancer. Nat Rev Cancer. 2023;23:474\u201390.","journal-title":"Nat Rev Cancer"},{"key":"1207_CR13","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1038\/s41467-023-36377-4","volume":"14","author":"J Rong","year":"2022","unstructured":"Rong J, Haider A, Jeppesen TE, Josephson L, Liang SH. Radiochemistry for positron emission tomography. Nat Commun. 2022;14:3257.","journal-title":"Nat Commun"},{"key":"1207_CR14","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1007\/s00259-019-04404-6","volume":"46","author":"O Israel","year":"2019","unstructured":"Israel O, Pellet O, Biassoni L, Palma DD, Estrada-Lobato E, Gnanasegaran G, et al. Two decades of SPECT\/CT \u2013 the coming of age of a technology: an updated review of literature evidence. Eur J Nucl Med Mol Imaging. 2019;46:1990\u20132012.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1207_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1007\/s00259-013-2685-3","volume":"41","author":"MR Bernsen","year":"2014","unstructured":"Bernsen MR, Vaissier PEB, Holen RV, Booij J, Beekman FJ, de Jong M. The role of preclinical SPECT in oncological and neurological research in combination with either CT or MRI. Eur J Nucl Med Mol Imaging. 2014;41:36\u201349.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1207_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13550-016-0164-0","volume":"6","author":"EK Fung","year":"2016","unstructured":"Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, et al. Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. EJNMMI Res. 2016;6:7.","journal-title":"EJNMMI Res"},{"key":"1207_CR17","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00259-013-2679-1","volume":"41","author":"SM Cheal","year":"2014","unstructured":"Cheal SM, Punzalan B, Doran MG, Evans MJ, Osborne JR, Lewis JS, et al. Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear Immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. Eur J Nucl Med Mol Imaging. 2014;41:985\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1207_CR18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s11307-015-0842-8","volume":"17","author":"B Xu","year":"2015","unstructured":"Xu B, Shokeen M, Sudlow GP, Harpstrite SE, Liang K, Cheney PP, et al. Utilizing the multiradionuclide resolving power of SPECT and dual radiolabeled single molecules to assess treatment response of tumors. Mol Imaging Biol. 2015;17:671\u20139.","journal-title":"Mol Imaging Biol"},{"key":"1207_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Ther. 2022;7:93.","journal-title":"Signal Transduct Target Ther"},{"key":"1207_CR20","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.3390\/ijms23095023","volume":"23","author":"G Cri\u0219an","year":"2022","unstructured":"Cri\u0219an G, Moldovean-Cioroianu NS, Timaru D-G, Andrie\u0219 G, C\u0103inap C, Chi\u0219 V. Radiopharmaceuticals for PET and SPECT imaging: A literature review over the last decade. Int J Mol Sci. 2022;23:5023.","journal-title":"Int J Mol Sci"},{"key":"1207_CR21","first-page":"899","volume":"35","author":"LB Shih","year":"1994","unstructured":"Shih LB, Thorpe SR, Griffiths GL, Diril H, Ong GL, Hansen HJ, et al. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels. J Nucl Med. 1994;35:899\u2013908.","journal-title":"J Nucl Med"},{"key":"1207_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s002620050371","volume":"44","author":"RM Sharkey","year":"1997","unstructured":"Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother. 1997;44:179\u201388.","journal-title":"Cancer Immunol Immunother"},{"key":"1207_CR23","first-page":"s5714","volume":"55","author":"BE Rogers","year":"1995","unstructured":"Rogers BE, Franano FN, Duncan JR, Edwards WB, Anderson CJ, Connett JM, et al. Identification of metabolites of 111In-diethylenetriaminepentaacetic acid-monoclonal antibodies and antibody fragments in vivo. Cancer Res. 1995;55:s5714\u201320.","journal-title":"Cancer Res"},{"key":"1207_CR24","first-page":"2123","volume":"56","author":"OW Press","year":"1996","unstructured":"Press OW, Shan D, Howell-Clark J, Eary J, Appelbaum FR, Matthews D, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123\u20139.","journal-title":"Cancer Res"},{"key":"1207_CR25","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10549-021-06427-w","volume":"191","author":"GL Phillips","year":"2022","unstructured":"Phillips GL, Guo J, Kiefer JR, Proctor W, Yadav DB, Dybdal N, et al. Trastuzumab does not bind rat or mouse ErbB2\/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics. Breast Cancer Res Treat. 2022;191:303\u201317.","journal-title":"Breast Cancer Res Treat"},{"key":"1207_CR26","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1158\/1535-7163.MCT-11-0742-T","volume":"11","author":"CV Pastuskovas","year":"2012","unstructured":"Pastuskovas CV, Mundo EE, Williams SP, Nayak TK, Ho J, Ulufatu S, et al. Effects of Anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast Cancer model. Mol Cancer Ther. 2012;11:752\u201362.","journal-title":"Mol Cancer Ther"},{"key":"1207_CR27","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-20-1097","volume":"20","author":"MK Ramos","year":"2021","unstructured":"Ramos MK, Mandikian D, Serme\u00f1o LN, King A, Dent AT, Ho J, et al. Valency of HER2 targeting antibodies influences tumor cell internalization and penetration. Mol Cancer Ther. 2021;20:1956\u201365.","journal-title":"Mol Cancer Ther"},{"key":"1207_CR28","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/nprot.2007.20","volume":"2","author":"G Vaidyanathan","year":"2007","unstructured":"Vaidyanathan G, Zalutsky MR. Synthesis of N-succinimidyl 4-guanidinomethyl-3-[*I]iodobenzoate: a radio-iodination agent for labeling internalizing proteins and peptides. Nat Protoc. 2007;2:282\u20136.","journal-title":"Nat Protoc"},{"key":"1207_CR29","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","volume":"89","author":"P Carter","year":"1992","unstructured":"Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci. 1992;89:4285\u20139.","journal-title":"Proc Natl Acad Sci"},{"key":"1207_CR30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.jim.2018.11.015","volume":"465","author":"SM O\u2019Rourke","year":"2019","unstructured":"O\u2019Rourke SM, Yu B, Morales JF, Didinger CM, Alexander DL, Vollmers C, et al. Production of a Recombinant monoclonal antibody to herpes simplex virus glycoprotein D for immunoaffinity purification of tagged proteins. J Immunol Methods. 2019;465:31\u20138.","journal-title":"J Immunol Methods"},{"key":"1207_CR31","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/sj.bjc.6690114","volume":"79","author":"J Kurebayashi","year":"1999","unstructured":"Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, Tanaka K, et al. Isolation and characterization of a new human breast cancer cell line, KPL-4, expressing the Erb B family receptors and interleukin-6. Br J Cancer. 1999;79:707\u201317.","journal-title":"Br J Cancer"},{"key":"1207_CR32","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/ame2.12139","volume":"3","author":"G Silva-Santana","year":"2020","unstructured":"Silva-Santana G, Bax JC, Fernandes DCS, Bacellar DTL, Hooper C, Dias AASO, et al. Clinical hematological and biochemical parameters in Swiss, BALB\/c, C57BL\/6 and B6D2F1 Mus musculus. Anim Model Exp Med. 2020;3:304\u201315.","journal-title":"Anim Model Exp Med"},{"key":"1207_CR33","doi-asserted-by":"publisher","first-page":"505","DOI":"10.4161\/cc.8.3.7608","volume":"8","author":"UD Monte","year":"2009","unstructured":"Monte UD. Does the cell number 109 still really fit one gram of tumor tissue? Cell Cycle. 2009;8:505\u20136.","journal-title":"Cell Cycle"},{"key":"1207_CR34","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1287\/ijoc.1060.0175","volume":"19","author":"Z Ugray","year":"2007","unstructured":"Ugray Z, Lasdon L, Plummer J, Glover F, Kelly J, Mart\u00ed R. Scatter search and local NLP solvers: A multistart framework for global optimization. Inf J Comput. 2007;19:328\u201340.","journal-title":"Inf J Comput"},{"key":"1207_CR35","doi-asserted-by":"publisher","first-page":"2085535","DOI":"10.1080\/19420862.2022.2085535","volume":"14","author":"H Rafidi","year":"2022","unstructured":"Rafidi H, Rajan S, Urban K, Shatz-Binder W, Hui K, Ferl GZ, et al. Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies. mAbs. 2022;14:2085535.","journal-title":"mAbs"},{"key":"1207_CR36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.4161\/mabs.23684","volume":"5","author":"DK Shah","year":"2013","unstructured":"Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. mAbs. 2013;5:297\u2013305.","journal-title":"mAbs"},{"key":"1207_CR37","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1158\/1535-7163.MCT-18-0977","volume":"18","author":"F Li","year":"2019","unstructured":"Li F, Ulrich ML, Shih VF-S, Cochran JH, Hunter JH, Westendorf L, et al. Mouse strains influence clearance and efficacy of antibody and antibody-drug conjugate via Fc-Fc\u03b3R interaction. Mol Cancer Ther. 2019;18:780\u20137.","journal-title":"Mol Cancer Ther"},{"key":"1207_CR38","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.1158\/0008-5472.CAN-13-3622-T","volume":"74","author":"TT Junttila","year":"2014","unstructured":"Junttila TT, Li J, Johnston J, Hristopoulos M, Clark R, Ellerman D, et al. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells. Cancer Res. 2014;74:5561\u201371.","journal-title":"Cancer Res"},{"key":"1207_CR39","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1096\/fj.14-269043","volume":"29","author":"OL Blanchard","year":"2015","unstructured":"Blanchard OL, Smoliga JM. Translating dosages from animal models to human clinical trials\u2014revisiting body surface area scaling. FASEB J. 2015;29:1629\u201334.","journal-title":"FASEB J"},{"key":"1207_CR40","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.xphs.2020.05.025","volume":"110","author":"H-P Chang","year":"2021","unstructured":"Chang H-P, Kim SJ, Shah DK. Whole-Body pharmacokinetics of antibody in mice determined using Enzyme-Linked immunosorbent assay and derivation of tissue interstitial concentrations. J Pharm Sci. 2021;110:446\u201357.","journal-title":"J Pharm Sci"},{"key":"1207_CR41","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jtbi.2012.08.034","volume":"314","author":"GM Thurber","year":"2012","unstructured":"Thurber GM, Wittrup KD. A mechanistic compartmental model for total antibody uptake in tumors. J Theor Biol. 2012;314:57\u201368.","journal-title":"J Theor Biol"},{"key":"1207_CR42","doi-asserted-by":"crossref","unstructured":"Wijngaarden JE, Jauw YWS, Zwezerijnen GJC, Veen BJ, de Vugts W, Zijlstra DJ et al. JM,. Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET. EJNMMI Res. 2024;14:18.","DOI":"10.1186\/s13550-024-01079-5"},{"key":"1207_CR43","doi-asserted-by":"publisher","first-page":"438","DOI":"10.2967\/jnumed.119.239558","volume":"62","author":"GAMS van Dongen","year":"2021","unstructured":"van Dongen GAMS, Beaino W, Windhorst AD, Zwezerijnen GJC, Oprea-Lager DE, Hendrikse NH, et al. The role of 89Zr-Immuno-PET in navigating and derisking the development of biopharmaceuticals. J Nucl Med. 2021;62:438\u201345.","journal-title":"J Nucl Med"},{"key":"1207_CR44","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.2967\/jnumed.118.224568","volume":"60","author":"YWS Jauw","year":"2019","unstructured":"Jauw YWS, O\u2019Donoghue JA, Zijlstra JM, Hoekstra OS, van Oordt CWMderH, Morschhauser F, et al. 89Zr-Immuno-PET: toward a noninvasive clinical tool to measure target engagement of therapeutic antibodies in vivo. J Nucl Med. 2019;60:1825\u201332.","journal-title":"J Nucl Med"},{"key":"1207_CR45","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1080\/19420862.2018.1521132","volume":"10","author":"D Mandikian","year":"2018","unstructured":"Mandikian D, Rafidi H, Adhikari P, Venkatraman P, Nazarova L, Fung G, et al. Site-specific conjugation allows modulation of click reaction stoichiometry for pretargeted SPECT imaging. mAbs. 2018;10:1269\u201380.","journal-title":"mAbs"},{"key":"1207_CR46","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1002\/jps.20178","volume":"93","author":"ED Lobo","year":"2004","unstructured":"Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645\u201368.","journal-title":"J Pharm Sci"},{"key":"1207_CR47","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1385\/IR:25:2:097","volume":"25","author":"V Ghetie","year":"2002","unstructured":"Ghetie V, Ward ES. Transcytosis and catabolism of antibody. Immunol Res. 2002;25:97\u2013113.","journal-title":"Immunol Res"},{"key":"1207_CR48","doi-asserted-by":"publisher","first-page":"1993769","DOI":"10.1080\/19420862.2021.1993769","volume":"13","author":"S Liu","year":"2021","unstructured":"Liu S, Verma A, Kettenberger H, Richter WF, Shah DK. Effect of variable domain charge on in vitro and in vivo disposition of monoclonal antibodies. mAbs. 2021;13:1993769.","journal-title":"mAbs"},{"key":"1207_CR49","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1158\/0008-5472.CAN-17-1958","volume":"78","author":"SK Sharma","year":"2018","unstructured":"Sharma SK, Chow A, Monette S, Vivier D, Pourat J, Edwards KJ, et al. Fc-mediated anomalous biodistribution of therapeutic antibodies in immunodeficient mouse models. Cancer Res. 2018;78:1820\u201332.","journal-title":"Cancer Res"},{"key":"1207_CR50","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.18632\/oncotarget.13869","volume":"8","author":"R Swiercz","year":"2016","unstructured":"Swiercz R, Mo M, Khare P, Schneider Z, Ober RJ, Ward ES. Loss of expression of the recycling receptor, FcRn, promotes tumor cell growth by increasing albumin consumption. Oncotarget. 2016;8:3528\u201341.","journal-title":"Oncotarget"},{"key":"1207_CR51","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2012.46.3653","volume":"31","author":"RK Jain","year":"2013","unstructured":"Jain RK. Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013;31:2205\u201318.","journal-title":"J Clin Oncol"},{"key":"1207_CR52","doi-asserted-by":"publisher","first-page":"902","DOI":"10.2967\/jnumed.118.214726","volume":"60","author":"CW van Oordt","year":"2019","unstructured":"Menke-van der Houven van Oordt CW, McGeoch A, Bergstrom M, McSherry I, Smith DA, Cleveland M, et al. Immuno-PET imaging to assess target engagement: experience from 89Zr-Anti-HER3 mAb (GSK2849330) in patients with solid tumors. J Nucl Med. 2019;60:902\u20139.","journal-title":"J Nucl Med"},{"key":"1207_CR53","doi-asserted-by":"publisher","first-page":"6128","DOI":"10.1158\/1078-0432.CCR-17-0311","volume":"23","author":"F Bensch","year":"2017","unstructured":"Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Hooge MNL, van Scheltinga AGTT, et al. 89Zr-Lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment in patients with solid tumors. Clin Cancer Res. 2017;23:6128\u201337.","journal-title":"Clin Cancer Res"},{"key":"1207_CR54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2967\/jnumed.118.210294","volume":"60","author":"S-K Woo","year":"2019","unstructured":"Woo S-K, Jang SJ, Seo M-J, Park JH, Kim BS, Kim EJ, et al. Development of 64Cu-NOTA-Trastuzumab for HER2 targeting: A radiopharmaceutical with improved pharmacokinetics for human studies. J Nucl Med. 2019;60:26\u201333.","journal-title":"J Nucl Med"},{"key":"1207_CR55","doi-asserted-by":"crossref","unstructured":"Gaykema SBM, de Jong JR, Perik PJ, Brouwers AH, Schr\u00f6der CP, Munnink THO, et al. 111In-Trastuzumab scintigraphy in HER2-Positive metastatic breast Cancer patients remains feasible during trastuzumab treatment. Mol Imaging. 2014;13:7290. 2014.00011.","DOI":"10.2310\/7290.2014.00011"},{"key":"1207_CR56","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.1091\/mbc.e04-07-0591","volume":"15","author":"CD Austin","year":"2004","unstructured":"Austin CD, Mazi\u00e8re AMD, Pisacane PI, van Dijk SM, Eigenbrot C, Sliwkowski MX, et al. Endocytosis and sorting of ErbB2 and the site of action of Cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell. 2004;15:5268\u201382.","journal-title":"Mol Biol Cell"},{"key":"1207_CR57","doi-asserted-by":"publisher","first-page":"12709","DOI":"10.1038\/s41598-019-49019-x","volume":"9","author":"M Fehling-Kaschek","year":"2019","unstructured":"Fehling-Kaschek M, Peckys DB, Kaschek D, Timmer J, de Jonge N. Mathematical modeling of drug-induced receptor internalization in the HER2-positive SKBR3 breast cancer cell-line. Sci Rep. 2019;9:12709.","journal-title":"Sci Rep"},{"key":"1207_CR58","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.clbc.2011.03.018","volume":"11","author":"HA Burris","year":"2011","unstructured":"Burris HA, Tibbitts J, Holden SN, Sliwkowski MX, Phillips GDL. Trastuzumab emtansine (T-DM1): A novel agent for targeting HER2 + Breast Cancer. Clin Breast Cancer. 2011;11:275\u201382.","journal-title":"Clin Breast Cancer"},{"key":"1207_CR59","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1158\/0008-5472.CAN-17-1638","volume":"78","author":"C Cilliers","year":"2017","unstructured":"Cilliers C, Menezes B, Nessler I, Linderman J, Thurber G. Improved tumor penetration and Single-Cell targeting of antibody drug conjugates increases anticancer efficacy and host survival. Cancer Res. 2017;78:758\u201368.","journal-title":"Cancer Res"},{"key":"1207_CR60","doi-asserted-by":"publisher","first-page":"11230","DOI":"10.7150\/thno.45273","volume":"10","author":"B Meng","year":"2020","unstructured":"Meng B, Folaron MR, Strawbridge RR, Sadeghipour N, Samkoe KS, Tichauer K, et al. Noninvasive quantification of target availability during therapy using paired-agent fluorescence tomography. Theranostics. 2020;10:11230\u201343.","journal-title":"Theranostics"},{"key":"1207_CR61","first-page":"14","volume":"11","author":"F Xiao","year":"2021","unstructured":"Xiao F, Li J, Huang K, Li X, Xiong Y, Wu M, et al. Macropinocytosis: mechanism and targeted therapy in cancers. Am J cancer Res. 2021;11:14\u201330.","journal-title":"Am J cancer Res"},{"key":"1207_CR62","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/sj.leu.2403205","volume":"18","author":"I Jedema","year":"2004","unstructured":"Jedema I, Barge RMY, van der Velden VHJ, Nijmeijer BA, van Dongen JJM, Willemze R, et al. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia. 2004;18:316\u201325.","journal-title":"Leukemia"}],"container-title":["EJNMMI Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01207-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13550-025-01207-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13550-025-01207-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T17:57:23Z","timestamp":1740419843000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmires.springeropen.com\/articles\/10.1186\/s13550-025-01207-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,24]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1207"],"URL":"https:\/\/doi.org\/10.1186\/s13550-025-01207-9","relation":{},"ISSN":["2191-219X"],"issn-type":[{"value":"2191-219X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,24]]},"assertion":[{"value":"12 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animals were maintained in accordance with the Guide for the Care and Use of Laboratory Animals (National Research Council 2011). Genentech is an AAALAC-accredited facility and all animal activities in this research study were conducted under protocols approved by the Genentech Institutional Animal Care and Use Committee (IACUC).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of Genentech, a member of the Roche Group, and have financial interest in Roche.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}